The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
10 2019
Historique:
received: 03 03 2019
revised: 22 08 2019
accepted: 24 08 2019
pubmed: 9 9 2019
medline: 25 8 2020
entrez: 9 9 2019
Statut: ppublish

Résumé

The aim of this study is to investigate the association between environmental factors (smoking, coffee, pesticide exposure) and Parkinson's disease (PD) subtypes (early-onset, mid-and-late onset, familial and sporadic) in the Greek population. The Hellenic Biobank of PD recorded information of PD cases and controls from two centers in Greece during 2006-2017. Patients with the A53T mutation in SNCA or GBA mutations were excluded. Associations of environmental factors with PD overall (and PD subtypes) versus controls were explored with logistic regression models adjusting for age, gender and each environmental factor. 686 patients and 356 controls were included. Smoking was associated with a reduced risk of PD overall (OR 0.48, 95% CI 0.35-0.67), mid-and-late onset (0.46, 0.32-0.66), familial (0.53, 0.34-0.83) and sporadic (0.46, 0.32-0.65), but not early-onset PD. There was an inverse linear association with pack-years of smoking, except for early-onset PD. Early-onset PD was the only PD subtype inversely associated with coffee consumption when dichotomously treated. Compared to never-coffee drinkers, only those at the upper tertile had lower odds for PD overall (0.52, 0.29-0.91), early-onset (0.16, 0.05-0.53) and familial PD (0.36, 0.17-0.75). No associations were found between pesticides and PD. Our study shows that the well-known negative association of smoking with PD occurs across all PD subtypes in the Greek population, apart from early-onset PD. Early-onset PD was also most strongly inversely associated with coffee consumption, highlighting a potential distinct underlying physiopathology in this PD subset that may involve specific gene-environment interactions.

Identifiants

pubmed: 31494049
pii: S1353-8020(19)30369-4
doi: 10.1016/j.parkreldis.2019.08.013
pii:
doi:

Substances chimiques

Coffee 0
Pesticides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105-112

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Efthalia Angelopoulou (E)

1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Greece; 2nd Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Greece; Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece; Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Greece.

Maria Bozi (M)

1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Greece; 2nd Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Greece.

Athina-Maria Simitsi (AM)

1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Greece; 2nd Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Greece.

Christos Koros (C)

1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Greece; 2nd Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Greece.

Roubina Antonelou (R)

2nd Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Greece.

Nikolaos Papagiannakis (N)

1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Greece; 2nd Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Greece; Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece.

Matina Maniati (M)

Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece.

Dafni Poula (D)

Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Greece.

Maria Stamelou (M)

1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Greece; 2nd Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Greece.

Demetrios K Vassilatis (DK)

Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece.

Ioannis Michalopoulos (I)

Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Greece.

Styliani Geronikolou (S)

Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece.

Nikolaos Scarmeas (N)

1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Greece; Taub Institute for Research in Alzheimer's Disease and the Aging Brain, The Gertrude H. Sergievsky Center, Department of Neurology, Columbia University, New York, USA.

Leonidas Stefanis (L)

1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Greece; 2nd Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Greece; Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece. Electronic address: lstefanis@bioacademy.gr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH